Skip to search formSkip to main contentSkip to account menu

SB 242235

Known as: SB-242235, SB242235 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Species and response dependent differences in the effects of MAPK inhibitors on P2X7 receptor function
Recent studies have implicated the mitogen activated protein kinase (MAPK) in cellular permeability changes following P2X7… 
2002
2002
SB-242235, a selective inhibitor of p38 mitogenactivated protein kinase. I: Preclinical pharmacokinetics
1. SB-242235 (1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl) imidazole) is a potent and selective p38 MAP… 
2002
2002
SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: In vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man
1. Inhibition of p38 MAP kinase has been investigated extensively as a potential therapy for cytokine-mediated diseases such as… 
Review
2000
Review
2000
Potential of p38 inhibitors in the treatment of rheumatoid arthritis.
Rheumatoid arthritis (RA) is a chronic debilitating disease estimated to afflict 13% of the world population. Although palliative… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)